Congenital disorder of glycosylation (CDG)-Ih patient with a severe hepato-intestinal phenotype and evolving central nervous system pathology
We present the clinical, molecular, and biochemical diagnosis of a patient with congenital disorder of glycosylation (CDG)-Ih. We report significant brain dysfunction in this multisystem disease, further expanding its complex clinical spectrum.
AAT, α-1-antitrypsin, CDG, congenital disorder of glycosylation, CNS, central nervous system, CST, castanospermine, Dol-P, dolichyl-phosphate, Glc, glucose, GlcNAc, N-acetylglucosamine, HS, heparan sulfate, LLO, lipid-linked oligosaccharide, Man, mannose, PLE, protein-losing enteropathy, RT, Reverse transcription, PCR, polymerase chain reaction
To access this article, please choose from the options below
Supported by RO1 DK55615 to HHF, a postdoctoral fellowship from STINT/VR (K2004-99PK-14887-02B), Sweden, to Erik A. Eklund, and the Baylor College of Medicine Mental Retardation Research Center to Fernando Scaglia.Vibeke Westphal is currently affiliated with Novo Nordisk, A/S, DK-2760, Måløv, Denmark.
PII: S0022-3476(05)00714-6
doi:10.1016/j.jpeds.2005.07.042
© 2005 Elsevier Inc. All rights reserved.
